Related references
Note: Only part of the references are listed.MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
Tom Mikkelsen et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Gene Expression Profiling in Cancers of Unknown Primary Reply
Federico A. Monzon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis
Roy Torcuator et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Will integrin inhibitors have proangiogenic effects in the clinic?
Michael Weller et al.
NATURE MEDICINE (2009)
Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors
Andrew R. Reynolds et al.
NATURE MEDICINE (2009)
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro
Gabriele D. Maurer et al.
NEURO-ONCOLOGY (2009)
Expression of integrin αvβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature
Oliver Schnell et al.
BRAIN PATHOLOGY (2008)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Stem cell-related Self-Renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
Anastasia Murat et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma
Ilse Vlassenbroeck et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)
L. B. Nabors et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
L. Burt Nabors et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mechanisms of angiogenesis in gliomas
O. Kargiotis et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidemiology and etiology of gliomas
H Ohgaki et al.
ACTA NEUROPATHOLOGICA (2005)
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
ME Hegi et al.
CLINICAL CANCER RESEARCH (2004)
Genetic pathways to glioblastoma:: A population-based study
H Ohgaki et al.
CANCER RESEARCH (2004)
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours
FALM Eskens et al.
EUROPEAN JOURNAL OF CANCER (2003)
Nanomolar small molecule inhibitors for αvβ6, αvβ5, and αvβ3 integrins
SL Goodman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Share Paper
